A JAPANESE, PHASE 3, OPEN-LABEL, 14-WEEK STUDY OF DS-5565 IN PATIENTS WITH PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY WITH RENAL IMPAIRMENT OR POST-HERPETIC NEURALGIA WITH RENAL IMPAIRMENT
Phase of Trial: Phase III
Latest Information Update: 03 May 2017
At a glance
- Drugs Mirogabalin (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Adverse reactions; Registrational
- Sponsors Daiichi Sankyo Company
- 13 Apr 2017 Status changed from active, no longer recruiting to completed.
- 07 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 04 Nov 2016 Planned End Date changed from 1 Mar 2017 to 1 May 2017.